nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Cytarabine—Gemcitabine—kidney cancer	0.237	0.35	CrCrCtD
Vidarabine—Azacitidine—Gemcitabine—kidney cancer	0.225	0.333	CrCrCtD
Vidarabine—Decitabine—Gemcitabine—kidney cancer	0.215	0.317	CrCrCtD
Vidarabine—ADA—Purine salvage—APRT—kidney cancer	0.00761	0.0658	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—PPAT—kidney cancer	0.00571	0.0494	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—APRT—kidney cancer	0.00531	0.0459	CbGpPWpGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)—PAX6—kidney cancer	0.00434	0.0375	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—PPAT—kidney cancer	0.00388	0.0336	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—APRT—kidney cancer	0.00361	0.0312	CbGpPWpGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—PAX6—kidney cancer	0.0032	0.0277	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FOSL2—kidney cancer	0.0032	0.0277	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—PPAT—kidney cancer	0.00287	0.0248	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—PAX6—kidney cancer	0.00285	0.0246	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—APRT—kidney cancer	0.00267	0.0231	CbGpPWpGaD
Vidarabine—ADA—renal system—kidney cancer	0.00258	0.103	CbGeAlD
Vidarabine—Adenosine triphosphate—APAF1—kidney cancer	0.00238	0.468	CrCbGaD
Vidarabine—ADK—nephron tubule—kidney cancer	0.00232	0.0924	CbGeAlD
Vidarabine—DPP4—nephron tubule—kidney cancer	0.00224	0.0896	CbGeAlD
Vidarabine—ADK—renal system—kidney cancer	0.0021	0.084	CbGeAlD
Vidarabine—ADORA2A—gonad—kidney cancer	0.0021	0.0839	CbGeAlD
Vidarabine—DPP4—renal system—kidney cancer	0.00204	0.0814	CbGeAlD
Vidarabine—ADK—kidney—kidney cancer	0.00203	0.0812	CbGeAlD
Vidarabine—ADK—cortex of kidney—kidney cancer	0.00198	0.0791	CbGeAlD
Vidarabine—DPP4—kidney—kidney cancer	0.00197	0.0787	CbGeAlD
Vidarabine—ADA—Nucleotide metabolism—PPAT—kidney cancer	0.00195	0.0169	CbGpPWpGaD
Vidarabine—DPP4—cortex of kidney—kidney cancer	0.00192	0.0767	CbGeAlD
Vidarabine—ADK—gonad—kidney cancer	0.00189	0.0753	CbGeAlD
Vidarabine—ADK—cardiac atrium—kidney cancer	0.00188	0.0752	CbGeAlD
Vidarabine—ADA—Nucleotide metabolism—APRT—kidney cancer	0.00181	0.0157	CbGpPWpGaD
Vidarabine—Adenosine monophosphate—APRT—kidney cancer	0.00177	0.347	CrCbGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—EPAS1—kidney cancer	0.00172	0.0149	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VHL—kidney cancer	0.00172	0.0149	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—PGK1—kidney cancer	0.00165	0.0143	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—TCEB1—kidney cancer	0.00151	0.0131	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—TCEB2—kidney cancer	0.00151	0.0131	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—IL4R—kidney cancer	0.00146	0.0127	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—MME—kidney cancer	0.00132	0.0115	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—OGG1—kidney cancer	0.00125	0.0109	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—CASP2—kidney cancer	0.00116	0.01	CbGpPWpGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—kidney cancer	0.00108	0.00935	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—ACHE—kidney cancer	0.00106	0.00919	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CD34—kidney cancer	0.00106	0.00914	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—WT1—kidney cancer	0.00103	0.00892	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—ACHE—kidney cancer	0.00102	0.00878	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—PAX6—kidney cancer	0.000966	0.00835	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—kidney cancer	0.000962	0.00832	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—CTSD—kidney cancer	0.000961	0.00831	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—kidney cancer	0.000921	0.00797	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—FLT1—kidney cancer	0.0009	0.00779	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—BCHE—kidney cancer	0.000884	0.00765	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SLC2A1—kidney cancer	0.000841	0.00727	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ALK—kidney cancer	0.000827	0.163	CrCbGaD
Vidarabine—ADA—p73 transcription factor network—BRCA2—kidney cancer	0.000608	0.00526	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—HNF1B—kidney cancer	0.00059	0.0051	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—KCNMA1—kidney cancer	0.000575	0.00497	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TSC2—kidney cancer	0.000569	0.00492	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—GSTM1—kidney cancer	0.000544	0.00471	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—kidney cancer	0.000522	0.00452	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—KDR—kidney cancer	0.000519	0.00449	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—JUND—kidney cancer	0.000516	0.00446	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—EIF5B—kidney cancer	0.000506	0.00438	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—kidney cancer	0.000467	0.00404	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—POMC—kidney cancer	0.000457	0.00395	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CUL7—kidney cancer	0.000451	0.0039	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—HSPA9—kidney cancer	0.00043	0.00372	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—KIT—kidney cancer	0.000404	0.0035	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ACY1—kidney cancer	0.000376	0.00325	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MUC4—kidney cancer	0.000351	0.00303	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—HNF1B—kidney cancer	0.000339	0.00293	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ST3GAL2—kidney cancer	0.000334	0.00289	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—RELA—kidney cancer	0.000332	0.00287	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—KCNMA1—kidney cancer	0.00033	0.00286	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—kidney cancer	0.000328	0.00284	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—EGR1—kidney cancer	0.000328	0.00284	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—CTNNB1—kidney cancer	0.000326	0.00282	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—EEF2—kidney cancer	0.000326	0.00282	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PDHB—kidney cancer	0.00032	0.00277	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CD4—kidney cancer	0.000309	0.00267	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—kidney cancer	0.000307	0.00265	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CCBL1—kidney cancer	0.000301	0.0026	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUND—kidney cancer	0.000296	0.00256	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1B—kidney cancer	0.000291	0.00251	CbGpPWpGaD
Vidarabine—Acute coronary syndrome—Paclitaxel—kidney cancer	0.000288	0.00163	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—kidney cancer	0.000286	0.00248	CbGpPWpGaD
Vidarabine—Myocardial infarction—Paclitaxel—kidney cancer	0.000286	0.00162	CcSEcCtD
Vidarabine—Dyspnoea—Erlotinib—kidney cancer	0.000285	0.00161	CcSEcCtD
Vidarabine—Pain—Vinblastine—kidney cancer	0.000285	0.00161	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—kidney cancer	0.000285	0.00161	CcSEcCtD
Vidarabine—Pain—Everolimus—kidney cancer	0.000284	0.0016	CcSEcCtD
Vidarabine—Vomiting—Temsirolimus—kidney cancer	0.000284	0.0016	CcSEcCtD
Vidarabine—Shock—Sorafenib—kidney cancer	0.000283	0.0016	CcSEcCtD
Vidarabine—Dry mouth—Sunitinib—kidney cancer	0.000283	0.0016	CcSEcCtD
Vidarabine—Mediastinal disorder—Gemcitabine—kidney cancer	0.000282	0.0016	CcSEcCtD
Vidarabine—Rash—Temsirolimus—kidney cancer	0.000281	0.00159	CcSEcCtD
Vidarabine—Dermatitis—Temsirolimus—kidney cancer	0.000281	0.00159	CcSEcCtD
Vidarabine—Arrhythmia—Gemcitabine—kidney cancer	0.00028	0.00158	CcSEcCtD
Vidarabine—Headache—Temsirolimus—kidney cancer	0.000279	0.00158	CcSEcCtD
Vidarabine—Dizziness—Pazopanib—kidney cancer	0.000278	0.00157	CcSEcCtD
Vidarabine—Back pain—Vincristine—kidney cancer	0.000278	0.00157	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—kidney cancer	0.000277	0.0024	CbGpPWpGaD
Vidarabine—Ventricular tachycardia—Doxorubicin—kidney cancer	0.000276	0.00156	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—kidney cancer	0.000274	0.00155	CcSEcCtD
Vidarabine—Pain—Erlotinib—kidney cancer	0.000274	0.00155	CcSEcCtD
Vidarabine—Shock—Sunitinib—kidney cancer	0.000273	0.00154	CcSEcCtD
Vidarabine—Discomfort—Dactinomycin—kidney cancer	0.00027	0.00153	CcSEcCtD
Vidarabine—Vomiting—Pazopanib—kidney cancer	0.000267	0.00151	CcSEcCtD
Vidarabine—Bradycardia—Paclitaxel—kidney cancer	0.000267	0.00151	CcSEcCtD
Vidarabine—Rash—Pazopanib—kidney cancer	0.000265	0.0015	CcSEcCtD
Vidarabine—Nausea—Temsirolimus—kidney cancer	0.000265	0.0015	CcSEcCtD
Vidarabine—Dermatitis—Pazopanib—kidney cancer	0.000265	0.0015	CcSEcCtD
Vidarabine—Bronchospasm—Capecitabine—kidney cancer	0.000264	0.00149	CcSEcCtD
Vidarabine—Agitation—Vincristine—kidney cancer	0.000264	0.00149	CcSEcCtD
Vidarabine—Back pain—Gemcitabine—kidney cancer	0.000264	0.00149	CcSEcCtD
Vidarabine—Headache—Pazopanib—kidney cancer	0.000263	0.00149	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ITPR2—kidney cancer	0.000263	0.00227	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000262	0.00148	CcSEcCtD
Vidarabine—ADK—Metabolism—GLIPR1—kidney cancer	0.000261	0.00226	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPAT—kidney cancer	0.000261	0.00226	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Paclitaxel—kidney cancer	0.000261	0.00147	CcSEcCtD
Vidarabine—Abdominal discomfort—Capecitabine—kidney cancer	0.000258	0.00146	CcSEcCtD
Vidarabine—Dyspnoea—Sorafenib—kidney cancer	0.000257	0.00145	CcSEcCtD
Vidarabine—ADA—Metabolism—ACY1—kidney cancer	0.000256	0.00221	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000252	0.00143	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MME—kidney cancer	0.00025	0.00216	CbGpPWpGaD
Vidarabine—Nausea—Pazopanib—kidney cancer	0.00025	0.00141	CcSEcCtD
Vidarabine—Paraesthesia—Sunitinib—kidney cancer	0.000249	0.00141	CcSEcCtD
Vidarabine—Convulsion—Vincristine—kidney cancer	0.000249	0.00141	CcSEcCtD
Vidarabine—Hypertension—Vincristine—kidney cancer	0.000248	0.0014	CcSEcCtD
Vidarabine—Dyspnoea—Sunitinib—kidney cancer	0.000247	0.0014	CcSEcCtD
Vidarabine—Pain—Sorafenib—kidney cancer	0.000246	0.00139	CcSEcCtD
Vidarabine—Hypersensitivity—Vinblastine—kidney cancer	0.000245	0.00139	CcSEcCtD
Vidarabine—Hypersensitivity—Everolimus—kidney cancer	0.000244	0.00138	CcSEcCtD
Vidarabine—Tinnitus—Paclitaxel—kidney cancer	0.000244	0.00138	CcSEcCtD
Vidarabine—Flushing—Paclitaxel—kidney cancer	0.000243	0.00138	CcSEcCtD
Vidarabine—Cardiac disorder—Paclitaxel—kidney cancer	0.000243	0.00138	CcSEcCtD
Vidarabine—ADK—Metabolism—APRT—kidney cancer	0.000242	0.0021	CbGpPWpGaD
Vidarabine—ADK—Metabolism—FH—kidney cancer	0.000242	0.0021	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000239	0.00135	CcSEcCtD
Vidarabine—Asthenia—Vinblastine—kidney cancer	0.000239	0.00135	CcSEcCtD
Vidarabine—Asthenia—Everolimus—kidney cancer	0.000238	0.00135	CcSEcCtD
Vidarabine—Cough—Gemcitabine—kidney cancer	0.000238	0.00134	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—AKAP13—kidney cancer	0.000237	0.00205	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP2—kidney cancer	0.000237	0.00205	CbGpPWpGaD
Vidarabine—Pain—Sunitinib—kidney cancer	0.000237	0.00134	CcSEcCtD
Vidarabine—Mediastinal disorder—Paclitaxel—kidney cancer	0.000236	0.00134	CcSEcCtD
Vidarabine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000236	0.00134	CcSEcCtD
Vidarabine—Hypertension—Gemcitabine—kidney cancer	0.000235	0.00133	CcSEcCtD
Vidarabine—Myocardial infarction—Capecitabine—kidney cancer	0.000235	0.00133	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—kidney cancer	0.000234	0.00133	CcSEcCtD
Vidarabine—Arrhythmia—Paclitaxel—kidney cancer	0.000234	0.00132	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MYC—kidney cancer	0.000234	0.00202	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—HSPD1—kidney cancer	0.000232	0.00201	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—RPL14—kidney cancer	0.000232	0.00201	CbGpPWpGaD
Vidarabine—Chest pain—Gemcitabine—kidney cancer	0.000232	0.00131	CcSEcCtD
Vidarabine—Asthenia—Erlotinib—kidney cancer	0.00023	0.0013	CcSEcCtD
Vidarabine—Discomfort—Gemcitabine—kidney cancer	0.000229	0.0013	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—OR4C13—kidney cancer	0.000229	0.00198	CbGpPWpGaD
Vidarabine—Urticaria—Sorafenib—kidney cancer	0.000229	0.00129	CcSEcCtD
Vidarabine—ADK—Metabolism—GPC3—kidney cancer	0.000228	0.00197	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Vincristine—kidney cancer	0.000227	0.00128	CcSEcCtD
Vidarabine—Pain—Dactinomycin—kidney cancer	0.000224	0.00127	CcSEcCtD
Vidarabine—Tension—Paclitaxel—kidney cancer	0.000224	0.00127	CcSEcCtD
Vidarabine—Dysgeusia—Paclitaxel—kidney cancer	0.000223	0.00126	CcSEcCtD
Vidarabine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000222	0.00126	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—kidney cancer	0.000222	0.00192	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CA2—kidney cancer	0.000222	0.00192	CbGpPWpGaD
Vidarabine—Nervousness—Paclitaxel—kidney cancer	0.000222	0.00125	CcSEcCtD
Vidarabine—Back pain—Paclitaxel—kidney cancer	0.000221	0.00125	CcSEcCtD
Vidarabine—Dizziness—Vinblastine—kidney cancer	0.00022	0.00125	CcSEcCtD
Vidarabine—Dizziness—Everolimus—kidney cancer	0.000219	0.00124	CcSEcCtD
Vidarabine—Hypotension—Vincristine—kidney cancer	0.000219	0.00124	CcSEcCtD
Vidarabine—Bradycardia—Capecitabine—kidney cancer	0.000219	0.00124	CcSEcCtD
Vidarabine—ADA—Metabolism—PDHB—kidney cancer	0.000217	0.00188	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALAD—kidney cancer	0.000216	0.00187	CbGpPWpGaD
Vidarabine—Vision blurred—Paclitaxel—kidney cancer	0.000215	0.00122	CcSEcCtD
Vidarabine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000215	0.00122	CcSEcCtD
Vidarabine—Hypoaesthesia—Capecitabine—kidney cancer	0.000214	0.00121	CcSEcCtD
Vidarabine—Tremor—Paclitaxel—kidney cancer	0.000214	0.00121	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000214	0.00121	CcSEcCtD
Vidarabine—Hypersensitivity—Sorafenib—kidney cancer	0.000212	0.0012	CcSEcCtD
Vidarabine—Vomiting—Vinblastine—kidney cancer	0.000212	0.0012	CcSEcCtD
Vidarabine—Dizziness—Erlotinib—kidney cancer	0.000212	0.0012	CcSEcCtD
Vidarabine—Vomiting—Everolimus—kidney cancer	0.000211	0.00119	CcSEcCtD
Vidarabine—ADK—Metabolism—ST3GAL2—kidney cancer	0.000211	0.00182	CbGpPWpGaD
Vidarabine—Paraesthesia—Vincristine—kidney cancer	0.00021	0.00119	CcSEcCtD
Vidarabine—Agitation—Paclitaxel—kidney cancer	0.00021	0.00119	CcSEcCtD
Vidarabine—Rash—Everolimus—kidney cancer	0.000209	0.00118	CcSEcCtD
Vidarabine—Dermatitis—Everolimus—kidney cancer	0.000209	0.00118	CcSEcCtD
Vidarabine—Headache—Vinblastine—kidney cancer	0.000209	0.00118	CcSEcCtD
Vidarabine—Angioedema—Paclitaxel—kidney cancer	0.000208	0.00118	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—OR4C13—kidney cancer	0.000208	0.0018	CbGpPWpGaD
Vidarabine—Headache—Everolimus—kidney cancer	0.000208	0.00118	CcSEcCtD
Vidarabine—Hypotension—Gemcitabine—kidney cancer	0.000208	0.00118	CcSEcCtD
Vidarabine—Asthenia—Sorafenib—kidney cancer	0.000207	0.00117	CcSEcCtD
Vidarabine—ADK—Metabolism—ALDH1A1—kidney cancer	0.000206	0.00178	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—kidney cancer	0.000205	0.00178	CbGpPWpGaD
Vidarabine—Cardiac failure—Doxorubicin—kidney cancer	0.000205	0.00116	CcSEcCtD
Vidarabine—Syncope—Paclitaxel—kidney cancer	0.000205	0.00116	CcSEcCtD
Vidarabine—ADA—Metabolism—CCBL1—kidney cancer	0.000204	0.00177	CbGpPWpGaD
Vidarabine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000204	0.00116	CcSEcCtD
Vidarabine—Hypersensitivity—Sunitinib—kidney cancer	0.000204	0.00115	CcSEcCtD
Vidarabine—Vomiting—Erlotinib—kidney cancer	0.000204	0.00115	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000203	0.00115	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—ITPR2—kidney cancer	0.000202	0.00175	CbGpPWpGaD
Vidarabine—Rash—Erlotinib—kidney cancer	0.000202	0.00114	CcSEcCtD
Vidarabine—Dermatitis—Erlotinib—kidney cancer	0.000202	0.00114	CcSEcCtD
Vidarabine—Palpitations—Paclitaxel—kidney cancer	0.000202	0.00114	CcSEcCtD
Vidarabine—Headache—Erlotinib—kidney cancer	0.000201	0.00113	CcSEcCtD
Vidarabine—Tinnitus—Capecitabine—kidney cancer	0.000201	0.00113	CcSEcCtD
Vidarabine—Loss of consciousness—Paclitaxel—kidney cancer	0.000201	0.00113	CcSEcCtD
Vidarabine—Pain—Vincristine—kidney cancer	0.0002	0.00113	CcSEcCtD
Vidarabine—Paraesthesia—Gemcitabine—kidney cancer	0.0002	0.00113	CcSEcCtD
Vidarabine—Flushing—Capecitabine—kidney cancer	0.0002	0.00113	CcSEcCtD
Vidarabine—Cardiac disorder—Capecitabine—kidney cancer	0.0002	0.00113	CcSEcCtD
Vidarabine—Cough—Paclitaxel—kidney cancer	0.000199	0.00113	CcSEcCtD
Vidarabine—Asthenia—Sunitinib—kidney cancer	0.000199	0.00112	CcSEcCtD
Vidarabine—Dyspnoea—Gemcitabine—kidney cancer	0.000198	0.00112	CcSEcCtD
Vidarabine—Nausea—Vinblastine—kidney cancer	0.000198	0.00112	CcSEcCtD
Vidarabine—Somnolence—Gemcitabine—kidney cancer	0.000198	0.00112	CcSEcCtD
Vidarabine—ADK—Metabolism—PGK1—kidney cancer	0.000198	0.00171	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC5A3—kidney cancer	0.000198	0.00171	CbGpPWpGaD
Vidarabine—Convulsion—Paclitaxel—kidney cancer	0.000198	0.00112	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—kidney cancer	0.000197	0.00112	CcSEcCtD
Vidarabine—Nausea—Everolimus—kidney cancer	0.000197	0.00111	CcSEcCtD
Vidarabine—Hypertension—Paclitaxel—kidney cancer	0.000197	0.00111	CcSEcCtD
Vidarabine—Chest pain—Paclitaxel—kidney cancer	0.000194	0.0011	CcSEcCtD
Vidarabine—ADK—Metabolism—LDHB—kidney cancer	0.000194	0.00168	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Capecitabine—kidney cancer	0.000194	0.0011	CcSEcCtD
Vidarabine—Anxiety—Paclitaxel—kidney cancer	0.000194	0.00109	CcSEcCtD
Vidarabine—Hypersensitivity—Dactinomycin—kidney cancer	0.000193	0.00109	CcSEcCtD
Vidarabine—Arrhythmia—Capecitabine—kidney cancer	0.000192	0.00109	CcSEcCtD
Vidarabine—Discomfort—Paclitaxel—kidney cancer	0.000192	0.00109	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—ACHE—kidney cancer	0.000192	0.00166	CbGpPWpGaD
Vidarabine—Cardiac arrest—Doxorubicin—kidney cancer	0.000191	0.00108	CcSEcCtD
Vidarabine—Dizziness—Sorafenib—kidney cancer	0.00019	0.00108	CcSEcCtD
Vidarabine—Pain—Gemcitabine—kidney cancer	0.00019	0.00108	CcSEcCtD
Vidarabine—Nausea—Erlotinib—kidney cancer	0.00019	0.00108	CcSEcCtD
Vidarabine—Dry mouth—Paclitaxel—kidney cancer	0.00019	0.00107	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—kidney cancer	0.00019	0.00107	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—EIF4EBP1—kidney cancer	0.000189	0.00164	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EGR1—kidney cancer	0.000188	0.00163	CbGpPWpGaD
Vidarabine—Asthenia—Dactinomycin—kidney cancer	0.000188	0.00106	CcSEcCtD
Vidarabine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000186	0.00105	CcSEcCtD
Vidarabine—Dysgeusia—Capecitabine—kidney cancer	0.000183	0.00104	CcSEcCtD
Vidarabine—Dizziness—Sunitinib—kidney cancer	0.000183	0.00104	CcSEcCtD
Vidarabine—Shock—Paclitaxel—kidney cancer	0.000183	0.00104	CcSEcCtD
Vidarabine—Vomiting—Sorafenib—kidney cancer	0.000183	0.00104	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—PAX6—kidney cancer	0.000182	0.00158	CbGpPWpGaD
Vidarabine—Tachycardia—Paclitaxel—kidney cancer	0.000182	0.00103	CcSEcCtD
Vidarabine—Rash—Sorafenib—kidney cancer	0.000182	0.00103	CcSEcCtD
Vidarabine—Dermatitis—Sorafenib—kidney cancer	0.000181	0.00103	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—CTSD—kidney cancer	0.000181	0.00157	CbGpPWpGaD
Vidarabine—Back pain—Capecitabine—kidney cancer	0.000181	0.00102	CcSEcCtD
Vidarabine—Headache—Sorafenib—kidney cancer	0.00018	0.00102	CcSEcCtD
Vidarabine—Hyperhidrosis—Paclitaxel—kidney cancer	0.00018	0.00102	CcSEcCtD
Vidarabine—ADA—Metabolism—PPAT—kidney cancer	0.000177	0.00153	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GLIPR1—kidney cancer	0.000177	0.00153	CbGpPWpGaD
Vidarabine—Vision blurred—Capecitabine—kidney cancer	0.000176	0.000998	CcSEcCtD
Vidarabine—Vomiting—Sunitinib—kidney cancer	0.000176	0.000997	CcSEcCtD
Vidarabine—Tremor—Capecitabine—kidney cancer	0.000175	0.000992	CcSEcCtD
Vidarabine—Rash—Sunitinib—kidney cancer	0.000175	0.000988	CcSEcCtD
Vidarabine—Dermatitis—Sunitinib—kidney cancer	0.000175	0.000987	CcSEcCtD
Vidarabine—Hypotension—Paclitaxel—kidney cancer	0.000174	0.000984	CcSEcCtD
Vidarabine—Headache—Sunitinib—kidney cancer	0.000174	0.000982	CcSEcCtD
Vidarabine—Hypersensitivity—Vincristine—kidney cancer	0.000173	0.000977	CcSEcCtD
Vidarabine—Nausea—Sorafenib—kidney cancer	0.000171	0.000967	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00017	0.000959	CcSEcCtD
Vidarabine—Asthenia—Vincristine—kidney cancer	0.000168	0.000951	CcSEcCtD
Vidarabine—ADK—Metabolism—CA9—kidney cancer	0.000168	0.00145	CbGpPWpGaD
Vidarabine—Syncope—Capecitabine—kidney cancer	0.000168	0.000949	CcSEcCtD
Vidarabine—Paraesthesia—Paclitaxel—kidney cancer	0.000167	0.000945	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—BCHE—kidney cancer	0.000167	0.00144	CbGpPWpGaD
Vidarabine—Vomiting—Dactinomycin—kidney cancer	0.000167	0.000943	CcSEcCtD
Vidarabine—Dyspnoea—Paclitaxel—kidney cancer	0.000166	0.000939	CcSEcCtD
Vidarabine—Somnolence—Paclitaxel—kidney cancer	0.000166	0.000936	CcSEcCtD
Vidarabine—Palpitations—Capecitabine—kidney cancer	0.000165	0.000936	CcSEcCtD
Vidarabine—Rash—Dactinomycin—kidney cancer	0.000165	0.000936	CcSEcCtD
Vidarabine—ADA—Metabolism—APRT—kidney cancer	0.000165	0.00143	CbGpPWpGaD
Vidarabine—ADA—Metabolism—FH—kidney cancer	0.000165	0.00143	CbGpPWpGaD
Vidarabine—Nausea—Sunitinib—kidney cancer	0.000165	0.000931	CcSEcCtD
Vidarabine—Loss of consciousness—Capecitabine—kidney cancer	0.000165	0.000931	CcSEcCtD
Vidarabine—Cough—Capecitabine—kidney cancer	0.000163	0.000924	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—POMC—kidney cancer	0.000162	0.0014	CbGpPWpGaD
Vidarabine—Hypertension—Capecitabine—kidney cancer	0.000162	0.000914	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—kidney cancer	0.00016	0.000905	CcSEcCtD
Vidarabine—Asthenia—Gemcitabine—kidney cancer	0.00016	0.000902	CcSEcCtD
Vidarabine—Chest pain—Capecitabine—kidney cancer	0.000159	0.000901	CcSEcCtD
Vidarabine—Pain—Paclitaxel—kidney cancer	0.000159	0.0009	CcSEcCtD
Vidarabine—Anxiety—Capecitabine—kidney cancer	0.000159	0.000898	CcSEcCtD
Vidarabine—Discomfort—Capecitabine—kidney cancer	0.000157	0.000891	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000157	0.00136	CbGpPWpGaD
Vidarabine—Dry mouth—Capecitabine—kidney cancer	0.000156	0.000882	CcSEcCtD
Vidarabine—Nausea—Dactinomycin—kidney cancer	0.000156	0.000881	CcSEcCtD
Vidarabine—Dizziness—Vincristine—kidney cancer	0.000155	0.000877	CcSEcCtD
Vidarabine—ADA—Metabolism—GPC3—kidney cancer	0.000155	0.00134	CbGpPWpGaD
Vidarabine—Drowsiness—Doxorubicin—kidney cancer	0.000154	0.000873	CcSEcCtD
Vidarabine—ADA—Metabolism—CA2—kidney cancer	0.000151	0.0013	CbGpPWpGaD
Vidarabine—Shock—Capecitabine—kidney cancer	0.00015	0.00085	CcSEcCtD
Vidarabine—Tachycardia—Capecitabine—kidney cancer	0.000149	0.000843	CcSEcCtD
Vidarabine—Vomiting—Vincristine—kidney cancer	0.000149	0.000843	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—kidney cancer	0.000148	0.000837	CcSEcCtD
Vidarabine—Urticaria—Paclitaxel—kidney cancer	0.000148	0.000836	CcSEcCtD
Vidarabine—Rash—Vincristine—kidney cancer	0.000148	0.000836	CcSEcCtD
Vidarabine—Hyperhidrosis—Capecitabine—kidney cancer	0.000148	0.000835	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—kidney cancer	0.000148	0.000835	CcSEcCtD
Vidarabine—ADA—Metabolism—ALAD—kidney cancer	0.000147	0.00127	CbGpPWpGaD
Vidarabine—Headache—Vincristine—kidney cancer	0.000147	0.00083	CcSEcCtD
Vidarabine—ADA—Metabolism—ST3GAL2—kidney cancer	0.000143	0.00124	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CRABP1—kidney cancer	0.000143	0.00124	CbGpPWpGaD
Vidarabine—Hypotension—Capecitabine—kidney cancer	0.000143	0.000807	CcSEcCtD
Vidarabine—Vomiting—Gemcitabine—kidney cancer	0.000141	0.0008	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—kidney cancer	0.000141	0.000798	CcSEcCtD
Vidarabine—Rash—Gemcitabine—kidney cancer	0.00014	0.000793	CcSEcCtD
Vidarabine—ADA—Metabolism—ALDH1A1—kidney cancer	0.00014	0.00121	CbGpPWpGaD
Vidarabine—Dermatitis—Gemcitabine—kidney cancer	0.00014	0.000792	CcSEcCtD
Vidarabine—Headache—Gemcitabine—kidney cancer	0.000139	0.000788	CcSEcCtD
Vidarabine—Nausea—Vincristine—kidney cancer	0.000139	0.000787	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000139	0.000787	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000138	0.00078	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—JUN—kidney cancer	0.000138	0.00119	CbGpPWpGaD
Vidarabine—Paraesthesia—Capecitabine—kidney cancer	0.000137	0.000776	CcSEcCtD
Vidarabine—Hypersensitivity—Paclitaxel—kidney cancer	0.000137	0.000776	CcSEcCtD
Vidarabine—Dyspnoea—Capecitabine—kidney cancer	0.000136	0.00077	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC5A3—kidney cancer	0.000134	0.00116	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PGK1—kidney cancer	0.000134	0.00116	CbGpPWpGaD
Vidarabine—Asthenia—Paclitaxel—kidney cancer	0.000134	0.000755	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PTEN—kidney cancer	0.000133	0.00115	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ITPR2—kidney cancer	0.000133	0.00115	CbGpPWpGaD
Vidarabine—Nausea—Gemcitabine—kidney cancer	0.000132	0.000747	CcSEcCtD
Vidarabine—ADA—Metabolism—LDHB—kidney cancer	0.000132	0.00114	CbGpPWpGaD
Vidarabine—Pain—Capecitabine—kidney cancer	0.000131	0.000739	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—IGF2—kidney cancer	0.000129	0.00112	CbGpPWpGaD
Vidarabine—Tinnitus—Doxorubicin—kidney cancer	0.000129	0.000731	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—kidney cancer	0.000129	0.000728	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—kidney cancer	0.000129	0.000728	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—TSC2—kidney cancer	0.000128	0.00111	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000125	0.000707	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—kidney cancer	0.000124	0.0007	CcSEcCtD
Vidarabine—Dizziness—Paclitaxel—kidney cancer	0.000123	0.000696	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—OR4C13—kidney cancer	0.000123	0.00106	CbGpPWpGaD
Vidarabine—Urticaria—Capecitabine—kidney cancer	0.000121	0.000686	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTT1—kidney cancer	0.000121	0.00105	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ACHE—kidney cancer	0.000121	0.00105	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—ANXA1—kidney cancer	0.00012	0.00104	CbGpPWpGaD
Vidarabine—Tension—Doxorubicin—kidney cancer	0.000118	0.00067	CcSEcCtD
Vidarabine—Vomiting—Paclitaxel—kidney cancer	0.000118	0.000669	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—kidney cancer	0.000118	0.000668	CcSEcCtD
Vidarabine—Rash—Paclitaxel—kidney cancer	0.000117	0.000664	CcSEcCtD
Vidarabine—Dermatitis—Paclitaxel—kidney cancer	0.000117	0.000663	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—kidney cancer	0.000117	0.000663	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—kidney cancer	0.000117	0.00066	CcSEcCtD
Vidarabine—Headache—Paclitaxel—kidney cancer	0.000117	0.00066	CcSEcCtD
Vidarabine—ADK—Metabolism—SCARB1—kidney cancer	0.000115	0.000992	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CA9—kidney cancer	0.000114	0.000988	CbGpPWpGaD
Vidarabine—Vision blurred—Doxorubicin—kidney cancer	0.000114	0.000643	CcSEcCtD
Vidarabine—ADK—Metabolism—PTGS1—kidney cancer	0.000114	0.000982	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—kidney cancer	0.000113	0.00098	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ABCB1—kidney cancer	0.000113	0.0222	CrCbGaD
Vidarabine—Hypersensitivity—Capecitabine—kidney cancer	0.000113	0.000637	CcSEcCtD
Vidarabine—ADK—Metabolism—PSMD7—kidney cancer	0.000111	0.000963	CbGpPWpGaD
Vidarabine—Agitation—Doxorubicin—kidney cancer	0.000111	0.000627	CcSEcCtD
Vidarabine—Nausea—Paclitaxel—kidney cancer	0.000111	0.000625	CcSEcCtD
Vidarabine—Asthenia—Capecitabine—kidney cancer	0.00011	0.00062	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—kidney cancer	0.000108	0.000612	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—kidney cancer	0.000107	0.000603	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—kidney cancer	0.000106	0.000921	CbGpPWpGaD
Vidarabine—Loss of consciousness—Doxorubicin—kidney cancer	0.000106	0.0006	CcSEcCtD
Vidarabine—ADK—Metabolism—BCHE—kidney cancer	0.000106	0.000913	CbGpPWpGaD
Vidarabine—Cough—Doxorubicin—kidney cancer	0.000105	0.000596	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—kidney cancer	0.000105	0.000591	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—LATS1—kidney cancer	0.000104	0.000903	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC5A5—kidney cancer	0.000104	0.000902	CbGpPWpGaD
Vidarabine—Hypertension—Doxorubicin—kidney cancer	0.000104	0.000589	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—kidney cancer	0.000103	0.000581	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—kidney cancer	0.000102	0.000579	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—kidney cancer	0.000102	0.000574	CcSEcCtD
Vidarabine—Dizziness—Capecitabine—kidney cancer	0.000101	0.000571	CcSEcCtD
Vidarabine—ADK—Metabolism—SLC2A1—kidney cancer	0.000101	0.000871	CbGpPWpGaD
Vidarabine—Dry mouth—Doxorubicin—kidney cancer	0.0001	0.000568	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—TSC2—kidney cancer	9.86e-05	0.000853	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Doxorubicin—kidney cancer	9.85e-05	0.000557	CcSEcCtD
Vidarabine—Vomiting—Capecitabine—kidney cancer	9.71e-05	0.000549	CcSEcCtD
Vidarabine—ADA—Metabolism—CRABP1—kidney cancer	9.71e-05	0.00084	CbGpPWpGaD
Vidarabine—Shock—Doxorubicin—kidney cancer	9.69e-05	0.000548	CcSEcCtD
Vidarabine—Rash—Capecitabine—kidney cancer	9.63e-05	0.000545	CcSEcCtD
Vidarabine—Dermatitis—Capecitabine—kidney cancer	9.62e-05	0.000544	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—kidney cancer	9.61e-05	0.000544	CcSEcCtD
Vidarabine—Headache—Capecitabine—kidney cancer	9.57e-05	0.000541	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—kidney cancer	9.52e-05	0.000538	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—AKAP13—kidney cancer	9.51e-05	0.000822	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—kidney cancer	9.2e-05	0.00052	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—kidney cancer	9.09e-05	0.000786	CbGpPWpGaD
Vidarabine—Nausea—Capecitabine—kidney cancer	9.08e-05	0.000513	CcSEcCtD
Vidarabine—ADA—Metabolism—ITPR2—kidney cancer	9.03e-05	0.000781	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	8.97e-05	0.000507	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—kidney cancer	8.89e-05	0.000769	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AMER1—kidney cancer	8.88e-05	0.000768	CbGpPWpGaD
Vidarabine—Paraesthesia—Doxorubicin—kidney cancer	8.84e-05	0.0005	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—kidney cancer	8.79e-05	0.000761	CbGpPWpGaD
Vidarabine—Dyspnoea—Doxorubicin—kidney cancer	8.78e-05	0.000497	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—kidney cancer	8.76e-05	0.000495	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—KIT—kidney cancer	8.71e-05	0.000753	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—kidney cancer	8.68e-05	0.000751	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKAP13—kidney cancer	8.64e-05	0.000747	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—POMC—kidney cancer	8.63e-05	0.000746	CbGpPWpGaD
Vidarabine—Pain—Doxorubicin—kidney cancer	8.42e-05	0.000476	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTP1—kidney cancer	8.4e-05	0.000726	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTT1—kidney cancer	8.24e-05	0.000712	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ACHE—kidney cancer	8.24e-05	0.000712	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—BRAF—kidney cancer	8.19e-05	0.000708	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—kidney cancer	8.14e-05	0.000704	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ITPR2—kidney cancer	8.09e-05	0.000699	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ABCB1—kidney cancer	7.95e-05	0.000688	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUN—kidney cancer	7.91e-05	0.000684	CbGpPWpGaD
Vidarabine—Urticaria—Doxorubicin—kidney cancer	7.82e-05	0.000442	CcSEcCtD
Vidarabine—ADA—Metabolism—SCARB1—kidney cancer	7.8e-05	0.000674	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—kidney cancer	7.72e-05	0.000668	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS1—kidney cancer	7.72e-05	0.000668	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	7.71e-05	0.000667	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—kidney cancer	7.65e-05	0.000661	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMD7—kidney cancer	7.57e-05	0.000655	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—kidney cancer	7.5e-05	0.000649	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GPC3—kidney cancer	7.44e-05	0.000644	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CER1—kidney cancer	7.44e-05	0.000644	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ITPR2—kidney cancer	7.34e-05	0.000635	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A1—kidney cancer	7.32e-05	0.000633	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—kidney cancer	7.26e-05	0.00041	CcSEcCtD
Vidarabine—ADA—Metabolism—BCHE—kidney cancer	7.17e-05	0.000621	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC5A5—kidney cancer	7.09e-05	0.000613	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—kidney cancer	7.07e-05	0.0004	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC2A1—kidney cancer	6.84e-05	0.000592	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAF1—kidney cancer	6.84e-05	0.000591	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RELA—kidney cancer	6.81e-05	0.000589	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ANXA1—kidney cancer	6.78e-05	0.000586	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—kidney cancer	6.76e-05	0.000585	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—kidney cancer	6.67e-05	0.000577	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—kidney cancer	6.51e-05	0.000368	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—kidney cancer	6.41e-05	0.000554	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SFRP2—kidney cancer	6.33e-05	0.000547	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—kidney cancer	6.26e-05	0.000542	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—kidney cancer	6.26e-05	0.000354	CcSEcCtD
Vidarabine—Rash—Doxorubicin—kidney cancer	6.21e-05	0.000351	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—kidney cancer	6.2e-05	0.000351	CcSEcCtD
Vidarabine—Headache—Doxorubicin—kidney cancer	6.17e-05	0.000349	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—kidney cancer	6.16e-05	0.000533	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ANXA1—kidney cancer	6.15e-05	0.000532	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—kidney cancer	6.1e-05	0.000527	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—POMC—kidney cancer	5.87e-05	0.000508	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—kidney cancer	5.85e-05	0.000331	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—kidney cancer	5.77e-05	0.000499	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—kidney cancer	5.76e-05	0.000498	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—kidney cancer	5.71e-05	0.000494	CbGpPWpGaD
Vidarabine—ADK—Metabolism—POMC—kidney cancer	5.45e-05	0.000472	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—kidney cancer	5.4e-05	0.000467	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—kidney cancer	5.29e-05	0.000458	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—kidney cancer	5.25e-05	0.000454	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—kidney cancer	5.22e-05	0.000451	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKAP13—kidney cancer	5.1e-05	0.000441	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP2—kidney cancer	5.1e-05	0.000441	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A1—kidney cancer	4.97e-05	0.00043	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK3—kidney cancer	4.93e-05	0.000426	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK1—kidney cancer	4.69e-05	0.000406	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRB7—kidney cancer	4.67e-05	0.000404	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—kidney cancer	4.43e-05	0.000383	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—kidney cancer	4.35e-05	0.000376	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ITPR2—kidney cancer	4.34e-05	0.000375	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—kidney cancer	4.07e-05	0.000352	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNA1—kidney cancer	3.93e-05	0.00034	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HSPB1—kidney cancer	3.91e-05	0.000338	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EIF4EBP1—kidney cancer	3.91e-05	0.000338	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—kidney cancer	3.79e-05	0.000328	CbGpPWpGaD
Vidarabine—ADA—Metabolism—POMC—kidney cancer	3.71e-05	0.000321	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMD7—kidney cancer	3.63e-05	0.000314	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TSC1—kidney cancer	3.63e-05	0.000314	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ANXA1—kidney cancer	3.63e-05	0.000314	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FLT1—kidney cancer	3.52e-05	0.000304	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—POMC—kidney cancer	3.32e-05	0.000287	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUNB—kidney cancer	3.26e-05	0.000282	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PAK1—kidney cancer	3.26e-05	0.000282	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—POMC—kidney cancer	3.01e-05	0.000261	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—kidney cancer	2.96e-05	0.000256	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—kidney cancer	2.68e-05	0.000232	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF2—kidney cancer	2.67e-05	0.000231	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN2B—kidney cancer	2.66e-05	0.00023	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—kidney cancer	2.58e-05	0.000223	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—kidney cancer	2.58e-05	0.000223	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAF1—kidney cancer	2.49e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—kidney cancer	2.45e-05	0.000212	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—kidney cancer	2.23e-05	0.000193	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—kidney cancer	2.12e-05	0.000184	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TSC2—kidney cancer	2.12e-05	0.000183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—kidney cancer	2.03e-05	0.000176	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—kidney cancer	1.87e-05	0.000162	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—kidney cancer	1.87e-05	0.000162	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—kidney cancer	1.82e-05	0.000157	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK3—kidney cancer	1.79e-05	0.000155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—POMC—kidney cancer	1.78e-05	0.000154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—kidney cancer	1.76e-05	0.000152	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK1—kidney cancer	1.7e-05	0.000147	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.63e-05	0.000141	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—kidney cancer	1.61e-05	0.000139	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—kidney cancer	1.48e-05	0.000128	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAF1—kidney cancer	1.47e-05	0.000127	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RELA—kidney cancer	1.46e-05	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—kidney cancer	1.45e-05	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—kidney cancer	1.43e-05	0.000124	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—kidney cancer	1.35e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—kidney cancer	1.32e-05	0.000114	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—kidney cancer	1.28e-05	0.000111	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—kidney cancer	1.28e-05	0.000111	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—kidney cancer	1.27e-05	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—kidney cancer	1.24e-05	0.000107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—kidney cancer	1.12e-05	9.68e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK3—kidney cancer	1.06e-05	9.15e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—kidney cancer	1.03e-05	8.9e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK1—kidney cancer	1.01e-05	8.71e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—kidney cancer	9.51e-06	8.23e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—kidney cancer	8.74e-06	7.56e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—kidney cancer	8.45e-06	7.31e-05	CbGpPWpGaD
